NCT00493571View on ClinicalTrials.gov

Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Myelodysplastic SyndromesMDS
Interventions
DRUG

Gimatecan

Starting dose: 0.6 mg capsules administered orally once daily.

Trial Locations (1)

77030

The University of Texas M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER